Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge.
about
Use of Vaxfectin adjuvant with DNA vaccine encoding the measles virus hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques against measles virusDissolving and biodegradable microneedle technologies for transdermal sustained delivery of drug and vaccineInfluenza virus-like particles containing M2 induce broadly cross protective immunityDevelopment of a vaccine against pandemic influenza viruses: current status and perspectives.Design of a heterosubtypic epitope-based peptide vaccine fused with hemokinin-1 against influenza viruses.Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments.Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses.Conservation and diversity of influenza A H1N1 HLA-restricted T cell epitope candidates for epitope-based vaccines.Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner.Cross-protective immunity to influenza A viruses.Influenza vaccine immunology.Novel vaccines against influenza viruses.New technologies for influenza vaccines.Protective efficacy of a broadly cross-reactive swine influenza DNA vaccine encoding M2e, cytotoxic T lymphocyte epitope and consensus H3 hemagglutinin.Virus-like particles as universal influenza vaccinesInfluenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in miceInhibition of influenza M2-induced cell death alleviates its negative contribution to vaccination efficiency.Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferretRobust immunity and heterologous protection against influenza in mice elicited by a novel recombinant NP-M2e fusion protein expressed in E. coliIn Vitro Evaluation of Influenza M2 and Leishmania major HSP70 (221-604) Chimer ProteinDNA vaccines: ready for prime time?Mucosal vaccination with recombinant Lactobacillus casei-displayed CTA1-conjugated consensus matrix protein-2 (sM2) induces broad protection against divergent influenza subtypes in BALB/c mice.The signal peptide sequence impacts the immune response elicited by a DNA epitope vaccine.Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice.Technologies for enhanced efficacy of DNA vaccines.Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral ChallengeThe proteosomal degradation of fusion proteins cannot be predicted from the proteosome susceptibility of their individual components.Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus.Novel linear DNA vaccines induce protective immune responses against lethal infection with influenza virus type A/H5N1.Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infectionCross-protection against drifted influenza viruses: options offered by adjuvanted and intradermal vaccinesHeterosubtypic protective immunity against widely divergent influenza subtypes induced by fusion protein 4sM2 in BALB/c mice.Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines.DNA vaccines: an historical perspective and view to the future.Cationic liposomal vaccine adjuvants in animal challenge models: overview and current clinical status.Vaxfectin adjuvant improves antibody responses of juvenile rhesus macaques to a DNA vaccine encoding the measles virus hemagglutinin and fusion proteins.Expression of H3N2 nucleoprotein in maize seeds and immunogenicity in mice.A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine.Monomeric M2e antigen in VesiVax® liposomes stimulates protection against type a strains of influenza comparable to liposomes with multimeric forms of M2e.Vaccines against epidemic and pandemic influenza
P2860
Q24658311-F4F4D96D-A17B-4889-9FC3-C64D2461A9B8Q27013822-1049047D-0213-43C8-8A10-AE601AE8B438Q28743472-FF20A6F6-D6C4-4B20-BD35-FF2919C4BF2FQ30373784-065926BE-1E7A-4170-9BDF-DF884D8564EEQ30373963-DD32938B-F2C6-4570-A9BF-3DD12C76D216Q30375991-93A9A330-C100-4DEC-AFE9-ABE00BBB18CFQ30382097-F1B8C872-2F65-4F9B-941E-ED6B968B1B3DQ30384675-77AB3478-3D68-43DA-911C-E422B39465CBQ30395315-6187D6A7-895C-405E-8FB8-90B85665BDD1Q30396399-F3BFA67F-E365-4BE6-BEC8-A196975A778DQ30398035-8B92DE01-4142-46F4-AD54-D74D1F76905BQ30407716-FE895FD0-1D50-4AB4-951A-EED584485F2CQ30411859-F6972767-F81E-4409-A1DF-57E85E01FB88Q30418612-D4EB50E4-C17F-4D64-A290-7E6A032226A1Q30421558-E9836FCB-60E7-4856-A097-31EBD6B61C39Q30425194-DDA08064-6F5E-4DFD-B14A-FF0A71764411Q33314897-9FDDF214-5379-42CD-B54F-48FBFF47B821Q33547457-827B1BB5-46E8-4BF9-80C0-09F95EA779FEQ34533990-369E03D0-1C04-4AA5-9442-3A9BA28B8E7DQ34629573-E2867756-F9FC-4AD9-AD0A-B712BF277B2AQ34824179-37F20EDE-8372-42B5-B5A3-D47AA22DE4ACQ35142923-3A6297FA-DBF8-41B9-9A20-93E0039A5B99Q35271066-5C70A744-A765-4C01-B721-ECB4C6B7B94AQ35656657-A72F0267-F614-4691-83BF-C44FFE34369EQ35802958-39705CE7-7ED5-48BB-AD66-70EB74F31665Q36104042-D1CE555B-EB5F-4E34-8DB6-98D0D8D7E4D8Q36662175-38FCB970-FF54-49DC-B95A-049E381B5B8DQ36694825-49F9D683-527D-493F-B06F-1132EAE08FBFQ37001633-3998D401-69BC-49A0-AA51-912B6E4FCE50Q37127506-A59712A8-4D98-4DA7-88BF-B76769FD9A21Q37478319-03395EE1-0EB5-48EF-B0EA-729AB4F8EA7CQ37582869-2886DAB5-8062-4830-ACE4-08DB4922EA52Q37813689-DA559C2F-9D28-43DB-B4D6-4F54DDD01357Q37825523-6B9F0CD7-4694-421F-9028-7C9F1AC35FFCQ38028994-CD799342-9465-45C8-9C16-228F8EB5AF19Q42079721-E4D6A7FC-22E5-4EB4-A56F-2120B1F4F305Q42166124-370ABAC3-B6AB-437B-BDA1-0A00D3A00A10Q44341358-86A06CB7-FC47-4B20-99C7-F12293356C8BQ44504298-0A41CAFE-4C78-4ECF-AA39-610621A2706DQ56550815-B9B4B0BF-C2DC-4B70-8A4B-865C8B6E998C
P2860
Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Vaxfectin-formulated influenza ...... gainst lethal viral challenge.
@ast
Vaxfectin-formulated influenza ...... gainst lethal viral challenge.
@en
type
label
Vaxfectin-formulated influenza ...... gainst lethal viral challenge.
@ast
Vaxfectin-formulated influenza ...... gainst lethal viral challenge.
@en
prefLabel
Vaxfectin-formulated influenza ...... gainst lethal viral challenge.
@ast
Vaxfectin-formulated influenza ...... gainst lethal viral challenge.
@en
P2093
P356
P1433
P1476
Vaxfectin-formulated influenza ...... gainst lethal viral challenge.
@en
P2093
Alain Rolland
Andrew Geall
Catherine J Luke
David C Kaslow
Denis Rusalov
Gretchen S Jimenez
Larry R Smith
Peggy Lalor
P304
P356
10.4161/HV.3.5.4175
P577
2007-03-20T00:00:00Z